The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
Open accessAbstract
The interindividual genetic variations in drug metabolizing enzymes and transporters influence the efficacy and toxicity of numerous drugs. As a fundamental element in precision medicine, pharmacogenomics, the study of responses of individuals to medication based on their genomic information, enables the evaluation of some specific genetic variants responsible for an individual’s particular drug response. In this article, we review the contributions of genetic polymorphisms to major individual variations in drug pharmacotherapy, focusing specifically on the pharmacogenomics of phase-I drug metabolizing enzymes and transporters. Substantial frequency differences in key variants of drug metabolizing enzymes and transporters, as well as their possible functional consequences, have also been discussed across geographic regions. The current effort illustrates the common presence of variability in drug responses among individuals and across all geographic regions. This information will aid health-care professionals in prescribing the most appropriate treatment aimed at achieving the best possible beneficial outcomes while avoiding unwanted effects for a particular patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms
The International SNP Map Working Group, Laboratories:, C. S. H., Sachidanandam, R., Weissman, D., Schmidt, S. C., Kakol, J. M., Stein, L. D., National Center for Biotechnology Information:, Marth, G., Sherry, S., et al. (2001) · Nature · doi:10.1038/35057149 · Cited by 2,977
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
Kimchi-Sarfaty, C., Oh, J. M., Kim, I.-W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., & Gottesman, M. M. (2007) · Science · doi:10.1126/science.1135308 · Cited by 2,416
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,365
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
Aithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,243
Drug Metabolism and Variability among Patients in Drug Response
Wilkinson, G. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmra032424 · Cited by 1,185
Ingelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1997) · Europe PMC (PubMed Central) · Cited by 973
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action
Shu, Y., Sheardown, S. A., Brown, C., Owen, R. P., Zhang, S., Castro, R. A., Ianculescu, A. G., Yue, L., Lo, J. C., Burchard, E. G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30558 · Cited by 967
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., & Goldstein, J. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40694-6 · Cited by 956
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
Miners, J. O., & Birkett, D. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00721.x · Cited by 844
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
Zanger, U. M., Raimundo, S., & Eichelbaum, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0832-2 · Cited by 795
Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3266 · Cited by 791
Genetic Control of Isoniazid Metabolism in Man
Evans, D. A. P., Manley, K. A., & McKusick, V. A. (1960) · BMJ · doi:10.1136/bmj.2.5197.485 · Cited by 784
Human ATP-binding cassette (ABC) transporter family
Vasiliou, V., Vasiliou, K., & Nebert, D. W. (2008) · Human Genomics · doi:10.1186/1479-7364-3-3-281 · Cited by 780
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants
Bradford, L. D. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.2.229 · Cited by 773
The Cytochrome P450 Superfamily: Biochemistry, Evolution and Drug Metabolism in Humans
P.B. Danielson, B. S. P. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337054 · Cited by 772
Wang, M., Roberts, D. L., Paschke, R., Shea, T. M., Masters, B. S. S., & Kim, J.-J. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8411 · Cited by 744
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
Pharmacogenomics and Individualized Drug Therapy
Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 720
Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review
Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., & Sadee, W. (2001) · JAMA · doi:10.1001/jama.286.18.2270 · Cited by 705
Codeine Intoxication Associated with Ultrarapid CYP2D6 Metabolism
Gasche, Y., Daali, Y., Fathi, M., Chiappe, A., Cottini, S., Dayer, P., & Desmeules, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041888 · Cited by 702
Lau, W. C., Waskell, L. A., Watkins, P. B., Neer, C. J., Horowitz, K., Hopp, A. S., Tait, A. R., Carville, D. G. M., Guyer, K. E., & Bates, E. R. (2003) · Circulation · doi:10.1161/01.cir.0000047060.60595.cc · Cited by 688
Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data
Lee, C. R., Goldstein, J. A., & Pieper, J. A. (2002) · Pharmacogenetics · doi:10.1097/00008571-200204000-00010 · Cited by 686
Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother
Koren, G., Cairns, J., Chitayat, D., Gaedigk, A., & Leeder, S. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69255-6 · Cited by 684
Mechanism of the Cardiotoxic Actions of Terfenadine
Woosley, R. L. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500120070028 · Cited by 646
Clinical application of pharmacogenetics
Spear, B. B., Heath-Chiozzi, M., & Huff, J. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)01986-4 · Cited by 646
Takeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C., Eriksson, N., Soranzo, N., Whittaker, P., Ranganath, V., Kumanduri, V., McLaren, W., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000433 · Cited by 632
Tirona, R. G., Leake, B. F., Merino, G., & Kim, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103792200 · Cited by 626
Molecular Basis of Ethnic Differences in Drug Disposition and Response
Xie, H.-G., Kim, R. B., Wood, A. J., & Stein, C. M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.815 · Cited by 600
Sibbing, D., Koch, W., Gebhard, D., Schuster, T., Braun, S., Stegherr, J., Morath, T., Schömig, A., von Beckerath, N., & Kastrati, A. (2010) · Circulation · doi:10.1161/circulationaha.109.885194 · Cited by 585
The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism
Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z.-Y., Kaminsky, L. S., Shenfleld, G. M., Miners, J. O., Birkett, D. J., & Goldstein, J. A. (1996) · Pharmacogenetics · doi:10.1097/00008571-199608000-00007 · Cited by 582
Nishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
Wojnowski, L., Kulle, B., Schirmer, M., Schlüter, G., Schmidt, A., Rosenberger, A., Vonhof, S., Bickeböller, H., Toliat, M. R., Suk, E.-K., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.576850 · Cited by 489
BORGES, S., DESTA, Z., LI, L., SKAAR, T., WARD, B., NGUYEN, A., JIN, Y., STORNIOLO, A., NIKOLOFF, D., & WU, L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.013 · Cited by 487
Aoyama, T., Yamano, S., Waxman, D. J., Lapenson, D. P., Meyer, U. A., Fischer, V, Tyndale, R., Inaba, T., Kalow, W., Gelboin, H. V., et al. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)81632-5 · Cited by 482
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230416.82349.90 · Cited by 470
Pharmacogenetics, Pharmacogenomics, and Individualized Medicine
Ma, Q., & Lu, A. Y. H. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003533 · Cited by 464
Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction
Chasman, D. I. (2004) · JAMA · doi:10.1001/jama.291.23.2821 · Cited by 453
Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs
Volpe, D. A., Tobin, G. A. M., Mellon, R. D., Katki, A. G., Parker, R. J., Colatsky, T., Kropp, T. J., & Verbois, S. L. (2011) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2010.12.007 · Cited by 446
Imai, Y., Nakane, M., Kage, K., Tsukahara, S., Ishikawa, E., Tsuruo, T., Miki, Y., & Sugimoto, Y. (2002) · PubMed · Cited by 442
SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 409
Kimura, S., Umeno, M., Skoda, R. C., Meyer, U., & Gonzalez, F. J. (1989) · Europe PMC (PubMed Central) · Cited by 404
Sistonen, J., Sajantila, A., Lao, O., Corander, J., Barbujani, G., & Fuselli, S. (2007) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000239974.69464.f2 · Cited by 398
Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., & Kamalipour, A. (2009) · Depression and Anxiety · doi:10.1002/da.20589 · Cited by 397
Christopher Gorski, J., Hall, S. D., Jones, D. R., & VandenBranden, M. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90543-6 · Cited by 395
Aklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F., & Ingelman-Sundberg, M. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20152-5 · Cited by 392
Identification of the Cytochrome P450 Enzymes Involved in the N-Oxidation of Voriconazole
Hyland, R., Jones, B. C., & Smith, D. A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.540 · Cited by 383
Marez, D., Legrand, M., Sabbagh, N., Lo Guidice, J.-M., Spire, C., Lafitte, J.-J., Meyer, U. A., & Broly, F. (1997) · Pharmacogenetics · doi:10.1097/00008571-199706000-00004 · Cited by 380
Clarke, T. A., & Waskell, L. A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.1.53 · Cited by 374
NIEMI, M., BACKMAN, J., KAJOSAARI, L., LEATHART, J., NEUVONEN, M., DALY, A., EICHELBAUM, M., KIVISTO, K., & NEUVONEN, P. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.018 · Cited by 360
ROLE OF ABCG2/BCRP IN BIOLOGY AND MEDICINE
Krishnamurthy, P., & Schuetz, J. D. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141238 · Cited by 356
Tzvetkov, M. V., Vormfelde, S. V., Balen, D., Meineke, I., Schmidt, T., Sehrt, D., Sabolić, I., Koepsell, H., & Brockmöller, J. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.92 · Cited by 349
Huang, N., Pandey, A. V., Agrawal, V., Reardon, W., Lapunzina, P. D., Mowat, D., Jabs, E. W., Vliet, G. V., Sack, J., Flück, C. E., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/429417 · Cited by 336
A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function
Fung, K. L., & Gottesman, M. M. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.02.014 · Cited by 335
Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K., Kawasaki, T., Hanai, H., Kubota, T., Ishizaki, T., & Kaneko, E. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-12-199812150-00006 · Cited by 335
Genetic susceptibility to adverse drug reactions
Pirmohamed, M., & Park, B. K. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01717-x · Cited by 328
Sakaeda, T., Nakamura, T., Horinouchi, M., Kakumoto, M., Ohmoto, N., Sakai, T., Morita, Y., Tamura, T., Aoyama, N., Hirai, M., et al. (2001) · Pharmaceutical Research · doi:10.1023/a:1012244520615 · Cited by 322
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations
Lamba, J. K., Lin, Y. S., Thummel, K., Daly, A., Watkins, P. B., Strom, S., Zhang, J., & Schuetz, E. G. (2002) · Pharmacogenetics · doi:10.1097/00008571-200203000-00006 · Cited by 316
Pharmacogenetics of Warfarin Elimination and Its Clinical Implications
Takahashi, H., & Echizen, H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140080-00003 · Cited by 312
Genetic association between sensitivity to warfarin and expression of CYP2C9*3
Steward, D. J., Haining, R. L., Henne, K. R., Davis, G., Rushmore, T. H., Trager, W. F., & Rettie, A. E. (1997) · Pharmacogenetics · doi:10.1097/00008571-199710000-00004 · Cited by 303
Tang, W. K. B.-K., & Endrenyi, L. (1998) · Pharmacogenetics · doi:10.1097/00008571-199808000-00001 · Cited by 299
Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
Mwinyi, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.016 · Cited by 293
The genetic basis of variability in drug responses
Roden, D. M., & George Jr, A. L. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd705 · Cited by 292
Dresser, M. J., Leabman, M. K., & Giacomini, K. M. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200104)90:4<397::aid-jps1000>3.0.co;2-d · Cited by 290
Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population*
Kubota, T., Chiba, K., & Ishizaki, T. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90214-3 · Cited by 288
Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactions
Magro, L., Moretti, U., & Leone, R. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.631910 · Cited by 287
Tang, K., Ngoi, S.-M., Gwee, P.-C., Chua, J. M. Z., Lee, E. J. D., Chong, S. S., & Lee, C. G. L. (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00004 · Cited by 285
OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine
Wang, Z.-J., Yin, O. Q. P., Tomlinson, B., & Chow, M. S. S. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328302cd41 · Cited by 281
Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches
Dietlein, F., Thelen, L., & Reinhardt, H. C. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.06.003 · Cited by 280
Hayer‐Zillgen, M., Brüss, M., & Bönisch, H. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704785 · Cited by 278
Furuya, H., Fernandez-Salguero, P., Gregory, W., Taber, H., Steward, A., Gonzalez, F. J., & Idle, J. R. (1995) · Pharmacogenetics · doi:10.1097/00008571-199512000-00008 · Cited by 278
genotype status and effect of omeprazole on intragastric pH in humans
FURUTA, T., OHASHI, K., KOSUGE, K., ZHAO, X., TAKASHIMA, M., KIMURA, M., NISHIMOTO, M., HANAI, H., KANEKO, E., & ISHIZAKI, T. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70075-5 · Cited by 272
Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin
Song, I., Shin, H., Shim, E., Jung, I., Kim, W., Shon, J., & Shin, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.61 · Cited by 268
Role of OATP Transporters in the Disposition of Drugs
Niemi, M. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.7.787 · Cited by 266
Aynacioglu, S., Brockmöller, J., Bauer, S., Sachse, C., Güzelbey, P., Öngen, Z., Nacak, M., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00012.x · Cited by 251
Association between ABCC2 Gene Haplotypes and Tenofovir‐Induced Proximal Tubulopathy
Izzedine, H., Hulot, J., Villard, E., Goyenvalle, C., Dominguez, S., Ghosn, J., Valantin, M. A., Lechat, P., & Deray, A. G. (2006) · The Journal of Infectious Diseases · doi:10.1086/508546 · Cited by 243
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype*1
SPARREBOOM, A. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.003 · Cited by 241
Identification of a polymorphically expressed member of the human cytochrome P-450III family.
Wrighton, S. A., Ring, B. J., Watkins, P. B., & VandenBranden, M. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09114-x · Cited by 228
Droździk, M., Białecka, M. A., liwiec, K. M., Honczarenko, K., Stankiewicz, J., & Sych, Z. (2003) · Pharmacogenetics · doi:10.1097/00008571-200305000-00004 · Cited by 227
Orr, S. T. M., Ripp, S. L., Ballard, T. E., Henderson, J. L., Scott, D. O., Obach, R. S., Sun, H., & Kalgutkar, A. S. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300065h · Cited by 225
Meier, Y., Pauli-Magnus, C., Zanger, U. M., Klein, K., Schaeffeler, E., Nussler, A. K., Nussler, N., Eichelbaum, M., Meier, P. J., & Stieger, B. (2006) · Hepatology · doi:10.1002/hep.21214 · Cited by 219
Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Zhou, S.-F., Ming Di, Y., Chan, E., Du, Y.-M., Chow, V., Xue, C., Lai, X., Wang, J.-C., Li, C., Tian, M., et al. (2008) · Current Drug Metabolism · doi:10.2174/138920008786049302 · Cited by 211
Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians
McLellan, R. A., Oscarson, M., Seidega??rd, J., Price Evans, D. A., & Ingelman-Sundberg, M. (1997) · Pharmacogenetics · doi:10.1097/00008571-199706000-00003 · Cited by 204
Siegmund, W., Ludwig, K., Giessmann, T., Dazert, P., Schroeder, E., Sperker, B., Warzok, R., Kroemer, H. K., & Cascorbi, I. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127739 · Cited by 199
A primer on the mechanics of P-glycoprotein the multidrug transporter
Hennessy, M., & Spiers, J. P. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2006.10.007 · Cited by 199
Pharmacogenetics of oral anticoagulants
Daly, A. K., & King, B. P. (2003) · Pharmacogenetics · doi:10.1097/00008571-200305000-00002 · Cited by 195
Li, J., Cusatis, G., Brahmer, J., Sparreboom, A., Robey, R. W., Bates, S. E., Hidalgo, M., & Baker, S. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.3.3763 · Cited by 191
Droździk, M., Białecka, M. A., Myśliwiec, K., Honczarenko, K., Stankiewicz, J., & Sych, Z. (2003) · PubMed · doi:10.1097/01.fpc.0000054087.48725.d9 · Cited by 189
Raimundo, S., Fischer, J., Eichelbaum, M., Griese, E.-U., Schwab, M., & Zanger, U. M. (2000) · Pharmacogenetics · doi:10.1097/00008571-200010000-00001 · Cited by 189
Yamauchi, A., Ieiri, I., Kataoka, Y., Tanabe, M., Nishizaki, T., Oishi, R., Higuchi, S., Otsubo, K., & Sugimachi, K. (2002) · Transplantation · doi:10.1097/00007890-200208270-00024 · Cited by 184
Takahashi, H., Kashima, T., Nomizo, Y., Muramoto, N., Shimizu, T., Nasu, K., Kubota, T., Kimura, S., & Echizen, H. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90103-5 · Cited by 183
CYP3A5 GENETIC POLYMORPHISMS IN DIFFERENT ETHNIC POPULATIONS
Roy, J.-N., Lajoie, J., Zijenah, L. S., Barama, A., Poirier, C., Ward, B. J., & Roger, M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.003822 · Cited by 182
Westphal, K. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.107579 · Cited by 177
Metformin Transport by Renal Basolateral Organic Cation Transporter hOCT2
Kimura, N., Okuda, M., & Inui, K.-I. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-1193-3 · Cited by 176
Kioka, N., Tsubota, J., Kakehi, Y., Komano, T., Gottesman, M. M., Pastan, I., & Ueda, K. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91985-2 · Cited by 175
Personalized Pharmacogenomics: Predicting Efficacy and Adverse Drug Reactions
Pirmohamed, M. (2014) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090413-025419 · Cited by 169
Kidd, R. S., Straughn, A. B., Meyer, M. C., Blaisdell, J., Goldstein, J. A., & Dalton, J. T. (1999) · Pharmacogenetics · doi:10.1097/00008571-199902000-00010 · Cited by 167
The Efficacy and Six-Week Tolerability of Simvastatin 80 and 160 mg/Day
Davidson, M. H., Stein, E. A., Dujovne, C. A., Hunninghake, D. B., Weiss, S. R., Knopp, R. H., Illingworth, D. R., Mitchel, Y. B., Melino, M. R., Zupkis, R. V., et al. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00742-4 · Cited by 167
Digoxin pharmacokinetics and MDR1 genetic polymorphisms
Verstuyft, C., Schwab, M., Schaeffeler, E., Kerb, R., Brinkmann, U., Jaillon, P., Funck-Brentano, C., & Becquemont, L. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0567-5 · Cited by 166
Tiroch, K. A., Sibbing, D., Koch, W., Roosen-Runge, T., Mehilli, J., Schömig, A., & Kastrati, A. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.06.039 · Cited by 166
P-GLYCOPROTEIN SYSTEM AS A DETERMINANT OF DRUG INTERACTIONS: THE CASE OF DIGOXIN–VERAPAMIL
VERSCHRAAGEN, M., KOKS, C. H. W., SCHELLENS, J. H. M., & BEIJNEN, J. H. (1999) · Pharmacological Research · doi:10.1006/phrs.1999.0535 · Cited by 159
Meyer, U. A., Zanger, U. M., & Schwab, M. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100502 · Cited by 157
Mikus, G., SCHOWEL, V., Drzewinska, M., Rengelshausen, J., DING, R., RIEDEL, K., Burhenne, J., WEISS, J., Thomsen, T., & Haefeli, W. E. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.04.004 · Cited by 157
Gerloff, T., Schaefer, M., Johne, A., Oselin, K., Meisel, C., Cascorbi, I., & Roots, I. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01691.x · Cited by 151
Frelinger, A. L., Lee, R. D., Mulford, D. J., Wu, J., Nudurupati, S. V., Nigam, A., Brooks, J. K., Bhatt, D. L., & Michelson, A. D. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.024 · Cited by 151
Tomlinson, B., Hu, M., Lee, V. W. Y., Lui, S. S. H., Chu, T. T. W., Poon, E. W. M., Ko, G. T. C., Baum, L., Tam, L., & Li, E. K. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.232 · Cited by 146
Pharmacogenomics of proton pump inhibitors
Furuta, T., Shirai, N., Sugimoto, M., Ohashi, K., & Ishizaki, T. (2004) · Pharmacogenomics · doi:10.1517/phgs.5.2.181.27483 · Cited by 139
The Pharmocogenomics of Warfarin: Closing in on Personalized Medicine
Rettie, A. E. (2006) · Molecular Interventions · doi:10.1124/mi.6.4.8 · Cited by 132
Iida, A., Saito, S., Sekine, A., Mishima, C., Kitamura, Y., Kondo, K., Harigae, S., Osawa, S., & Nakamura, Y. (2002) · Journal of Human Genetics · doi:10.1007/s100380200041 · Cited by 120
Pharmacogenomics of MRP Transporters (ABCC1-5) and BCRP (ABCG2)
Gradhand, U., & Kim, R. B. (2008) · Drug Metabolism Reviews · doi:10.1080/03602530801952617 · Cited by 109
Jung, F., Richardson, T. H., Raucy, J. L., & Johnson, E. F. (1997) · PubMed · Cited by 104
Genetic factors in the predisposition to drug-induced hypersensitivity reactions
Pirmohamed, M. (2006) · The AAPS Journal · doi:10.1208/aapsj080103 · Cited by 103
Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1)
Fujita, T., Brown, C., Carlson, E. J., Taylor, T. R., de la Cruz, M., Johns, S. J., Stryke, D., Kawamoto, M., Fujita, K., Castro, R. A., et al. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200504000-00003 · Cited by 102
Hart, S. N., Wang, S., Nakamoto, K., Wesselman, C., Li, Y., & Zhong, X.-B. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f2f121 · Cited by 99
Verbeurgt, P., Mamiya, T., & Oesterheld, J. R. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.6 · Cited by 99
Schwab, M. G., Schaeffeler, E., Klotz, U. E., & Treiber, G. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.05.002 · Cited by 97
Xiang, X., Jada, S. R., Li, H. H., Fan, L., Tham, L. S., Wong, C. I., Lee, S. C., Lim, R. S. C., Zhou, Q. Y., Goh, B. C., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230420.05221.71 · Cited by 93
Han, J., Lim, H., Shin, E., Yoo, Y.-K., Park, Y. H., Lee, J.-E., Kim, H. T., & Lee, J. S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.07.019 · Cited by 92
High and variable frequencies of CYP2C19 mutations
Kaneko, A., Lum, J. K., Yaviong, J., et al. (1999) · Pharmacogenetics · doi:10.1097/00008571-199910000-00005 · Cited by 90
Pharmacogenetic perspectives gained from twin and family studies
Vesell, E. S. (1989) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(89)90130-7 · Cited by 90
Pharmacogenomics of the Triazole Antifungal Agent Voriconazole
Mikus, G., Scholz, I. M., & Weiß, J. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.18 · Cited by 90
Genetic determinants of platelet response to clopidogrel
Kubica, A., Koziński, M., Grześk, G., Fabiszak, T., Navarese, E. P., & Goch, A. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0611-8 · Cited by 89
Conrad, S., Kauffmann, H.-M., Ito, K., Deeley, R. G., Cole, S. P. C., & Schrenk, D. (2001) · Journal of Human Genetics · doi:10.1007/s100380170017 · Cited by 87
Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy
Bluth, M. H., & Li, J. (2011) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s18861 · Cited by 79
Genomic Medicine, Precision Medicine, Personalized Medicine: What’s in a Name?
Roden, D. M., & Tyndale, R. F. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.101 · Cited by 79
Gough, A. C., Smith, C. A. D., Howell, S. M., Wolf, C. R., Bryant, S. P., & Spurr, N. K. (1993) · Genomics · doi:10.1006/geno.1993.1082 · Cited by 77
Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy
Lin, J. H. (2007) · Current Drug Metabolism · doi:10.2174/138920007779816002 · Cited by 75
Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro
Sandee, D., Morrissey, K., Agrawal, V., Tam, H. K., Kramer, M. A., Tracy, T. S., Giacomini, K. M., & Miller, W. L. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833f4f9b · Cited by 74
McCrea, J. B., Cribb, A. E., Rushmore, T. H., et al. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70114-1 · Cited by 73
Somogyi, A. A., & Bochner, F. (1984) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1984.tb02450.x · Cited by 66
Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?
Ma, T. K. W., Lam, Y., Tan, V. P. Y., & Yan, B. P. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03949.x · Cited by 63
Molecular diversity at the CYP2D6 locus in the Mediterranean region
Fuselli, S., Dupanloup, I., Frigato, E., Cruciani, F., Scozzari, R., Moral, P., Sistonen, J., Sajantila, A., & Barbujani, G. (2004) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201243 · Cited by 63
zu Schwabedissen, H. E. M., & Kim, R. B. (2009) · Molecular Pharmaceutics · doi:10.1021/mp9000298 · Cited by 62
High and variable frequencies of CYP2C19 mutations
Kaneko, A., Lum, J. K., Yaviong, J., Takahashi, N., Ishizaki, T., Bertilsson, L., Kobayakawa, T., & Björkman, A. (1999) · Pharmacogenetics and Genomics · doi:10.1097/01213011-199910000-00005 · Cited by 58
Tricyclic Antidepressant Plasma Levels after Fluoxetine Addition
Vandel, S., Bertschy, G., Bonin, B., et al. (2008) · Neuropsychobiology · doi:10.1159/000118838 · Cited by 57
Rothnie, A. J., Callaghan, R., Deeley, R. G., & Cole, S. P. C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600869200 · Cited by 56
Preskorn, S., SHAH, R., NEFF, M., Golbeck, A. L., & CHOI, J. (2007) · Journal of Psychiatric Practice · doi:10.1097/00131746-200701000-00002 · Cited by 53
Sündermann, A., & Oostenbrink, C. (2013) · Protein Science · doi:10.1002/pro.2307 · Cited by 52
Pharmacogenomics in oncology care
Filipski, K. K., Mechanic, L. E., Long, R. M., & Freedman, A. N. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00073 · Cited by 51
Genetic control of anticoagulation
Mannucci, P. M. (1999) · The Lancet · doi:10.1016/s0140-6736(98)00326-2 · Cited by 46
Personalized medicine: Striding from genes to medicines
Nair, S. (2010) · Perspectives in Clinical Research · doi:10.4103/2229-3485.71775 · Cited by 43
Yasumori, T., Chen, L., Li, Q., Ueda, M., Tsuzuki, T., Goldstein, J. A., Kato, R., & Yamazoe, Y. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00034-9 · Cited by 42
Xu, Z., Huang, S., Xiao, Z., et al. (1997) · Pharmacogenetics · doi:10.1097/00008571-199704000-00004 · Cited by 41
Zhu, L., Brüggemann, R. J. M., Uy, J. P., Colbers, A. P. H., Hruska, M. W., Chung, E., Sims, K., Vakkalagadda, B. J., Xu, X., van Schaik, R. H. N., et al. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.798 · Cited by 39
Of needles and haystacks: finding human disease genes by positional cloning.
Collins, F. (1991) · PubMed · Cited by 37
Pandey, A. V., Flück, C. E., & Mullis, P. E. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.08.072 · Cited by 36
Conseil, G., & Cole, S. P. C. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054213 · Cited by 28
Pharmacokinetic Factors Influencing Variability in Human Drug Response
Marchant, B. (1981) · Scandinavian Journal of Rheumatology · doi:10.3109/03009748109095328 · Cited by 27
Genetic Risk Prediction: Individualized Variability in Susceptibility to Toxicants
Nebert, D. W., Zhang, G., & Vesell, E. S. (2013) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140241 · Cited by 26
Létourneau, I. J., Slot, A. J., Deeley, R. G., & Cole, S. P. C. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015479 · Cited by 23
CYP2C9 Promoter Variable Number Tandem Repeat Polymorphism Regulates mRNA Expression in Human Livers
Wang, D., Sun, X., Gong, Y., Gawronski, B. E., Langaee, T. Y., Shahin, M. H., Khalifa, S. I., & Johnson, J. A. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.044255 · Cited by 16
Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphisms
Rafii, A., McGrath, S. D., Blinder, M. A., Buchman, T. G., Zehnbauer, B. A., & Freeman, B. D. (2001) · American Journal of Hematology · doi:10.1002/ajh.1094 · Cited by 15
Jin, Y., Chen, M., Penning, T. M., & Miller, W. L. (2015) · Biochemical Journal · doi:10.1042/bj20141410 · Cited by 6
ATP-Binding-Cassette Transporters in Biliary Efflux and Drug-Induced Liver Injury
Pedersen, J. M. (2013) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 4
Cited by
Vinarov, Z., Abdallah, M., Agundez, J. A. G., Allegaert, K., Basit, A. W., Braeckmans, M., Ceulemans, J., Corsetti, M., Griffin, B. T., Grimm, M., et al. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105812 · Cited by 359
Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
Kciuk, M., Marciniak, B., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144919 · Cited by 266
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
Mitophagy and cGAS–STING crosstalk in neuroinflammation
Zhou, X., Wang, J., Yu, L., Qiao, G., Qin, D., Yuen-Kwan Law, B., Ren, F., Wu, J., & Wu, A. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.012 · Cited by 131
Tomlinson, L., Ramsden, D., Leite, S. B., Beken, S., Bonzo, J. A., Brown, P., Candarlioglu, P. L., Chan, T. S., Chen, E., Choi, C. K., et al. (2024) · Advanced Biology · doi:10.1002/adbi.202300131 · Cited by 33
Metadata
- Authors
- Ahmed, S., Zhou, Z., Zhou, J., & Chen, S.-Q.
- Venue
- Genomics, Proteomics & Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10-01
- Volume
- 14
- Issue
- 5
- Pages
- 298-313
- ISSN
- 1672-0229 (ISSN-L)
- 2210-3244
- OpenAlex
- W2528806650
- Cited by
- 371
- References
- 161
- FWCI
- 21.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.